Compositions and methods for treating or limiting development of age-related macular degeneration
View Patent ↗The disclosure provides methods for treating or limiting development age-related macular degeneration, comprising (a) a GPR143 receptor agonist, including but not limited to L-DOPA, L-DOPA analogues, or a pharmaceutically acceptable salt thereof, and (b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof, and related compositions.
1. A method for treating or limiting development of age-related macular degeneration (AMD), comprising administering orally, topically to the eyes, or intranasally, in the evening, to a subject in need thereof an amount effective to treat or limit development of AMD of
(a) a GPR143 receptor agonist selected from the group consisting of L-DOPA, an L-DOPA analogue, and pharmaceutically acceptable salts thereof; and
(b) melatonin, a melatonin analogue selected from the group consisting of ramelteon, agomelatine and tasimelteon, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the GPR143 receptor agonist is selected from the group consisting of L-DOPA and-pharmaceutically acceptable salts thereof.
3. The method of claim 1 , wherein the administering is done in the evening two hours or less before the subject goes to bed.
4. The method of claim 1 , wherein the administering comprises oral administering.
5. The method of claim 1 , wherein the administering comprises administering by eye drops.
6. The method of claim 1 , wherein the administering comprises intranasal administering.
7. The method of claim 1 , wherein the method is for treating a subject with wet acute macular degeneration (AMD).
8. The method of claim 1 , wherein the method is for treating a subject with dry AMD.
9. The method of claim 1 , wherein the subject is undergoing anti-vascular endothelial growth factor therapy.
10. The method of claim 1 , wherein the subject has one or more of drusen deposits, lipofuscin deposits, or pseudodrusen (RPD) deposits.
11. The method of claim 1 , wherein the method further comprises treating the subject with light therapy.
12. The method of claim 1 , wherein the L-DOPA is in a form selected from the group consisting of L-DOPA esters and bile acid conjugates of L-DOPA.
13. The method of claim 1 , comprising administering to a subject in need thereof an amount effective to treat or limit development of AMD of:
(a) between 100 and 300 mg L-DOPA or a pharmaceutically acceptable salt thereof; and
(b) melatonin or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 comprising wherein the L-DOPA is administered in a dosage of 100 mg L-DOPA/day.
15. The method of claim 1 wherein the melatonin is administered in a dosage of between 1 and 10 mg melatonin/day.
16. The method of claim 1 wherein the GPR143 receptor agonist and the melatonin are administered once every two or three days.
17. The method of claim 15 wherein the melatonin is administered in a dosage of between 5 and 10 mg melatonin/day.